 |
|
New study shows that therapeutic gene expression can be sustainable for 1 year
October 26, 2007May pave the way to more effective, long lasting, and safer gene therapy treatments
Researchers at the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have shown for the first time that it is possible to sustain therapeutic gene expression in the central nervous system for up to a year, even in the presence of an anti-viral immune response mechanism that is normally present in humans.
The researchers demonstrated in an animal model that the delivery system for the gene, a novel gutted adenoviral vector called HC-Adv, is completely invisible to the immune system. Vectors previously used to deliver genes carried minute amounts of viral proteins that were detected by the immune system, triggering an immune response that rendered the therapeutic gene inactive after a period of weeks.
According to the researchers, this delivery system is safer and more effective than what is currently available, and should therefore advance clinical gene therapy trials for people suffering from central nervous system disorders such as Parkinson's, Alzheimer's, and Multiple Sclerosis. The research was sponsored in part by The National Institutes of Health.
Cedars-Sinai Medical Center
According to the researchers, this delivery system is safer and more effective than what is currently available, and should therefore advance clinical gene therapy trials for people suffering from central nervous system disorders such as Parkinson's, Alzheimer's, and Multiple Sclerosis. The research was sponsored in part by The National Institutes of Health.
Cedars-Sinai Medical Center
More Therapeutic Gene Expression Current Events and Therapeutic Gene Expression News Articles
|
Gene expression may be 'therapeutic target' for stroke.(Neuropsychiatric Medicine): An article from: Clinical Psychiatry News by Betsy Bates (Author) This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on February 1, 2006. The length of the article is 515 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Gene expression may be 'therapeutic target' for stroke.(Neuropsychiatric Medicine) Author: Betsy Bates Publication: Clinical Psychiatry News (Magazine/Journal) Date: February 1, 2006 Publisher: Thomson Gale Volume: 34 Issue: 2 Page: 59(1) Distributed by Thomson... | |
|
Signal Transduction Pathways, Chromatin Structure, and Gene Expression Mechanisms as Therapeutic Targets (Annals of the New York Academy of Sciences) by Marc Diederich (Editor) | |
 |
Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications, and Therapeutic Implications by Levon Michael Khachigian (Editor) In the post-genomic era we have, at our fingertips, an incredible array of genomic sequences from a multitude of complex organisms. There remains, however, the critical need to understand the precise roles individual genes play in complex biological milieu. Synthetic nucleic acids are at the cutting-edge of molecular strategies that target genes of interest in a specific, efficient and cost-effective manner. These tools are now being used as new and exciting gene-silencing agents in vitro, in a panoply of animal models, and as novel therapeutics in human disease. Synthetic Nucleic Acids as Inhibitors of Gene Expression: Mechanisms, Applications, and Therapeutic Implications brings together timely, authoritative reviews by renowned international leaders in the fields of ribozymes,... |
|
Gene Expression Neurogenesis and Healing Psychosocial Gebomics and Therapeutic Hypnosis / Sobriety and Ideomotor Questioning - american journal of clinical hypnosis January 2003 Vol 45 No 3 by american society of clinical hypnosis (Author) | |
 |
Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression (Annals of the New York Academy of Sciences) by Yoon S. Cho-Chung (Editor), Alan M. Gewirtz (Editor), Cy A. Stein (Editor) The potential for the development of therapeutic oligonucleotides into clinical medicines and their use as basic research tools are explored in this volume, which is the proceedings of the 7th NIH Symposium on Therapeutic Oligonucleotides. The focus is on antisense, RNAi, triple-helix, gene repair, DNA chips, and CpG immune modulatory oligonucleotides. Specific chapters address designing better siRNAs, splice switching oligonucleotides, selective delivery of oligonucleotides, and medicinal drugs by receptor-mediated endocytosis, development of a function overriding siRNA silencing in mammalian cells, transcription factor decoys, and modified oligonucleotide hybridization and genetic insertion. NOTE: Annals volumes are available for sale as individual books or... |
|
New Frontiers in the Study of Gene Functions (New Horizons in Therapeutics) by George Poste (Editor), Stanley T. Crooke (Editor) | |
|
Sirna Therapeutics granted two key patents on its RNA interference technology.: An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on February 1, 2005. The length of the article is 818 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Sirna Therapeutics granted two key patents on its RNA interference technology. Publication: BIOTECH Patent News (Newsletter) Date: February 1, 2005 Publisher: Biotech Patent News Volume: 19 Issue: 2 Distributed by Thomson Gale | |
 |
Imaging PET Reporter Transgenes in Living Subjects: Methods for Non-invasive Monitoring of Therapeutic Transgene Expression in Mice and Humans Using Positron Emission Tomography Reporter Genes by Shahriar Yaghoubi (Author) Non-invasive imaging of transgene expression should soon play a critical role in gene and adoptive cellular gene therapy clinical trials. Positron emission tomography (PET) reporter genes (PRG)/probes (PRP) are currently the most advanced technologies available for imaging transgens in humans. PRGs can be used to image the location, magnitude, and time variation of the intensity of transgene expression throughout the whole body of a patient. This can eliminate the need for multiple biopsies, which are potentially dangerous and yet do not provide a complete picture of whole body transgene expression at multiple time points. This dissertation provides details of several studies on direct and indirect imaging of therapeutic transgenes using multiple PRG/PRP systems in mice.... |
 |
Gene Profiles in Drug Design by Brett A. Lidbury (Editor), Suresh Mahalingam (Editor) With the successful mapping of the human genome, we have entered an age of unprecedented opportunity in which researchers are beginning to apply this vast repository of knowledge to the treatment of human disease. Gene-profiling technologies and the concept of individualized medicine are leading to the development of drugs with enhanced specificity. This promises to lead to more effective treatment of diseases with reduced risk of side effects. Gene Profiling in Drug Design provides insights from leaders in the pure sciences, biotechnology, and other arenas. It emphasizes the science that underpins gene profiling and drug development, and also includes clinical and ethical perspectives from experts in those fields. These explore the broadest health and social implications for this... |
| © 2009 BrightSurf.com |